XEMBIFY 200 mg/ml, solution for injection subcutaneous bottle, 10 ml
Active ingredients: IMMUNOGLOBULINE HUMAINE NORMALE (PLASMATIQUE)
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Solution for injectionbottle, 10 mlsous-cutanée
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- XEMBIFY 200 mg/mL, solution injectable sous-cutanée
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon(s) en verre avec fermeture à témoin d'effraction de 10 ml
- Marketing authorisation holder
- INSTITUTO GRIFOLS
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 25 Mar 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
67894931CIP73024408CIP133400930244081Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| IMMUNOGLOBULINE HUMAINE NORMALE (PLASMATIQUE)solution | 200 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.